#abiomed

Abiomed (ABMD): A look at what lies ahead for this medical device company

Shares of Abiomed Inc. (NASDAQ: ABMD) were down 4% in afternoon trade on Wednesday. The stock has dropped 22% over the past three months and 10% in the past one week. The company reported its third quarter 2020 earnings results last Thursday, beating earnings estimates but missing on revenue.

The stock was hurt by the revenue miss as well as by misleading reports by some researchers over the…

Abiomed, Inc. (NASDAQ: ABMD): Q3 2020 Earnings Snapshot

— Medical device maker Abiomed, Inc. (NASDAQ: ABMD) reported net income of $69.2 million or $1.51 per share for the third quarter of 2020, vs. $1.09 per share expected.

— Revenue increased 10% annually to $221.6 million during the three-month period, vs. $226.99 million expected

— US revenue rose 8% to $185.6 million, while overseas revenue moved up 29% to $36 million

— Third-quarter…

Abiomed misses Q1 2020 estimates; stock plunges

Abiomed (NASDAQ: ABMD) slipped more than 10% in the pre-market session as the company missed first quarter 2020 results. GAAP net income was $88.9 million, or $1.93 per diluted share compared to $90.1 million or $1.95 per share in the prior-year quarter. Revenue rose 15.4% to $207.7 million, but missed analysts prediction of $210.69 million.

“In Q1, we implemented new training programs,…

Abiomed to report Q4 2019 earnings results powered by Impella

Abiomed (NASDAQ: ABMD) is scheduled to release its fourth quarter results today before the bell. Investors would be expecting the medical device company continues the momentum from the last quarter powered by its flagship product Impella, which is expected to boost earnings in the near future.

For the fourth quarter, analysts are expecting earnings to jump 35% to $1.08 per share and revenue to…

Abiomed stock falls to yearly low

Abiomed Inc. (NASDAQ: ABMD) stock fell to a yearly low of $270.25 on Thursday. Investors remained concerned about the future of the provider of temporary mechanical circulatory support devices. However, a unique product portfolio and robust demand for its Impella line of products could be beneficial for the company.

The data from the company’s flagship Impella heart pump showed a significant…

Abiomed notiert bei 284 $ aktuell + 1 $